Abstract
Focal increased enhancement or radiopharmaceutical uptake in the liver has been associated with superior vena cava syndrome. This report describes the finding in a patient imaged with a relatively new agent, Tc-99m Apcitide. The collateral pathways responsible for the liver “hot spot” are reviewed, as is the role of Tc-99m Apcitide in deep venous thrombosis imaging.

This publication has 0 references indexed in Scilit: